Log in

OTCMKTS:IBXNFIBEX Technologies Stock Price, Forecast & News

0.00 (0.00 %)
(As of 05/12/2020)
Today's Range
Now: $0.10
50-Day Range
MA: $0.10
52-Week Range
Now: $0.10
Volume13 shs
Average Volume1,400 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; cartilage assays for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides services, such as filling and lyophilization for making disposable medical device components; and custom fermentation and micro dispensing of enzymes, as well as contract manufacturing. It serves manufacturers of medical devices, quality control labs, and academic research institutions. The company was founded in 1986 and is based in Montreal, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars

Industry, Sector and Symbol

Industry N/A



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive IBXNF News and Ratings via Email

Sign-up to receive the latest news and ratings for IBXNF and its competitors with MarketBeat's FREE daily newsletter.

IBEX Technologies (OTCMKTS:IBXNF) Frequently Asked Questions

How has IBEX Technologies' stock been impacted by COVID-19 (Coronavirus)?

IBEX Technologies' stock was trading at $0.1025 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IBXNF shares have increased by 0.5% and is now trading at $0.1030. View which stocks have been most impacted by Coronavirus.

How were IBEX Technologies' earnings last quarter?

IBEX Technologies Inc (OTCMKTS:IBXNF) announced its earnings results on Thursday, December, 19th. The company reported ($0.02) EPS for the quarter. View IBEX Technologies' earnings history.

Has IBEX Technologies been receiving favorable news coverage?

News stories about IBXNF stock have trended extremely negative recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. IBEX Technologies earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutIBEX Technologies.

Who are IBEX Technologies' key executives?

IBEX Technologies' management team includes the following people:
  • Mr. Paul Baehr, Pres, CEO & Chairman (Age 77)
  • Mr. Richard Collin, Director of Fin. & Sec.
  • Mahendra Kumar Pallapothu, VP of Operations
  • Mr. Claire Bergeron, VP of Admin.

What is IBEX Technologies' stock symbol?

IBEX Technologies trades on the OTCMKTS under the ticker symbol "IBXNF."

How do I buy shares of IBEX Technologies?

Shares of IBXNF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IBEX Technologies' stock price today?

One share of IBXNF stock can currently be purchased for approximately $0.10.

What is IBEX Technologies' official website?

The official website for IBEX Technologies is www.ibex.ca.

How can I contact IBEX Technologies?

The company can be reached via phone at 514-344-4004.

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.